Breaking News Instant updates and real-time market news.

SMMT

Summit Therapeutics

$10.80

0.2 (1.89%)

06:32
02/13/18
02/13
06:32
02/13/18
06:32

Summit Therapeutics initiated with a Buy at BTIG

BTIG analyst Timothy Chiang initiated Summit Therapeutics with a Buy rating and a price target of $33. Chiang says the company has positioned itself for upside with two pipeline products: ezutromid for the treatment of Duchenne Muscular Dystrophy, in Phase 2 with recently announced positive interim data, and ridinilazole antibiotic for the treatment of Clostridium infections, entering Phase 3 trials. Given that the former recently showed positive proof of concept data, the analyst contends that it provides additional support for the company's utrophin modulator - a potential new treatment for all 50K patients WW who suffer from DMD. Chiang sees the next potential catalyst for the stock as the release of additional results from its phaseout Phase 2 trial in about 40 patients in Q3 of this year.

  • 13

    Feb

SMMT Summit Therapeutics
$10.80

0.2 (1.89%)

01/04/18
RHCO
01/04/18
INITIATION
Target $24
RHCO
Buy
Summit Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Edward Nash initiated Summit Therapeutics (SMMT) with a Buy rating and a price target of $24. Nash says the company's ezutromid drug has the potential to address all 50K cases of Duchenne muscular dystrophy in the developed world, expecting the key interim data announced this quarter to be strong. The analyst notes that DMD remains a "high profile orphan disease", and only Sarepta's (SRPT) Exondys 51 treatment address about 13% of its patients.
01/25/18
HCWC
01/25/18
NO CHANGE
Target $16
HCWC
Buy
Summit Therapeutics data provide 'mixed signals,' says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says this morning's preliminary analysis from Summit Therapeutics' ongoing Duchenne muscular dystrophy Phase 2 study provides "mixed signals." There was a "compelling" decline in developmental myosin and an increase in mean utrophin protein, but these positive changes had limited readthrough into T2 MRI, 6MWT and NSAA, Chattopadhyay tells investors in a research note. The analyst believes that for the shares to "breakout," Summit needs to address its financing overhang and the 48-week readout needs to provide compelling evidence of disease stabilization. Chattopadhyay has a Buy rating on Summit Therapeutics with a $16 price target. The stock in late morning trading is up 24% to $15.14.
01/25/18
HCWC
01/25/18
NO CHANGE
Target $75
HCWC
Buy
H.C. Wainwright sees potential competitive advantages for Sarepta
H.C. Wainwright analyst Debjit Chattopadhyay says the "steady percolation of not so good news" that delayed the initial public offering of Solid Biosciences translates into potential competitive advantages for Sarepta Therapeutics (SRPT). In addition, the analyst believes Sarepta partner Summit Therapeutics' (SMMT) preliminary analysis this morning from its ongoing Duchenne muscular dystrophy Phase 2 study provided "mixed signals." Chattopadhyay keeps a Buy rating on Sarepta with a $75 price target. The stock in afternoon trading is up 3%, or $2.17, to $67.95.
02/13/18
BTIG
02/13/18
INITIATION
Target $33
BTIG
Buy
Summit Therapeutics initiated with a Buy at BTIG
BTIG analyst Timothy Chiang started Summit Therapeutics with a Buy rating and $33 price target. The company is positioned for upside with its two pipeline products, ezutromid and ridinilazole, Chiang tells investors in a research note.

TODAY'S FREE FLY STORIES

WING

Wingstop

$46.78

1.05 (2.30%)

09:11
02/23/18
02/23
09:11
02/23/18
09:11
Recommendations
Wingstop analyst commentary  »

Wingstop model intact…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$351.58

-0.53 (-0.15%)

09:09
02/23/18
02/23
09:09
02/23/18
09:09
Recommendations
CoStar Group analyst commentary  »

CoStar Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 23

    May

TSS

TSYS

$86.80

0.24 (0.28%)

, MA

MasterCard

$172.95

0.63 (0.37%)

09:08
02/23/18
02/23
09:08
02/23/18
09:08
Hot Stocks
Netspend, MLB partner for team-branded GPR prepaid cards »

Prepaid card provider…

TSS

TSYS

$86.80

0.24 (0.28%)

MA

MasterCard

$172.95

0.63 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 08

    Mar

HMSY

HMS Holdings

$15.32

-0.06 (-0.39%)

09:06
02/23/18
02/23
09:06
02/23/18
09:06
Earnings
Breaking Earnings news story on HMS Holdings »

HMS Holdings reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

AABA

Altaba

$75.52

0.41 (0.55%)

09:06
02/23/18
02/23
09:06
02/23/18
09:06
Recommendations
Altaba analyst commentary  »

Altaba price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

AMZN

Amazon.com

$1,485.34

2.42 (0.16%)

09:05
02/23/18
02/23
09:05
02/23/18
09:05
Upgrade
Amazon.com rating change  »

Amazon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

GTLS

Chart Industries

$55.85

6.14 (12.35%)

09:05
02/23/18
02/23
09:05
02/23/18
09:05
Recommendations
Chart Industries analyst commentary  »

Chart Industries target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

PFE

Pfizer

$35.74

-0.02 (-0.06%)

09:04
02/23/18
02/23
09:04
02/23/18
09:04
Hot Stocks
Pfizer announces positive CHMP opinion for MYLOTARG, BOSULIF »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 04

    Apr

KZIA

Kazia Therapeutics

$4.99

0.43 (9.43%)

09:04
02/23/18
02/23
09:04
02/23/18
09:04
Hot Stocks
Kazia Therapeutics confirms FDA Orphan Designation for GDC-0084 »

Kazia Therapeutics is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIA

Acacia Communications

$41.84

-1.6 (-3.68%)

09:03
02/23/18
02/23
09:03
02/23/18
09:03
Recommendations
Acacia Communications analyst commentary  »

Piper remains optimistic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 13

    Mar

  • 29

    Mar

CLIR

ClearSign Combustion

$2.35

-0.2 (-7.84%)

09:02
02/23/18
02/23
09:02
02/23/18
09:02
Syndicate
ClearSign Combustion 5M share Spot Secondary priced at $2.26 »

National Securities acted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

GE

General Electric

$14.50

0.13 (0.90%)

09:02
02/23/18
02/23
09:02
02/23/18
09:02
Hot Stocks
General Electric signs $1B framework agreement in Ukraine »

GE Transportation signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QVCA

QVC Group

$28.23

0.07 (0.25%)

09:02
02/23/18
02/23
09:02
02/23/18
09:02
Hot Stocks
QVC Group says CFO Ted Jastrzebski to step down, new CFO search launched »

QVC announced that Ted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

REI

Ring Energy

$14.82

-0.77 (-4.94%)

09:01
02/23/18
02/23
09:01
02/23/18
09:01
Syndicate
Ring Energy 53.6M share Spot Secondary priced at $14.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

FDX

FedEx

$245.43

2.13 (0.88%)

09:00
02/23/18
02/23
09:00
02/23/18
09:00
Upgrade
FedEx rating change  »

FedEx upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

W

Wayfair

$73.95

-21.74 (-22.72%)

09:00
02/23/18
02/23
09:00
02/23/18
09:00
Recommendations
Wayfair analyst commentary  »

Wayfair price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSNN

Fusion Telecommunications

$2.85

0.05 (1.79%)

08:59
02/23/18
02/23
08:59
02/23/18
08:59
Recommendations
Fusion Telecommunications analyst commentary  »

Craig-Hallum sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

DLPH

Delphi Technologies

$50.15

0.11 (0.22%)

08:58
02/23/18
02/23
08:58
02/23/18
08:58
Conference/Events
Delphi Technologies management to meet with RBC Capital »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 26

    Apr

DLPH

Delphi Technologies

$50.15

0.11 (0.22%)

08:57
02/23/18
02/23
08:57
02/23/18
08:57
Conference/Events
Delphi Technologies management to meet with RBC Capital »

Group Breakfast Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 26

    Apr

TVTY

Tivity Health

08:56
02/23/18
02/23
08:56
02/23/18
08:56
Recommendations
Tivity Health analyst commentary  »

Tivity Health price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSTK

Shutterstock

$46.35

1.77 (3.97%)

08:55
02/23/18
02/23
08:55
02/23/18
08:55
Recommendations
Shutterstock analyst commentary  »

Shutterstock price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

GE

General Electric

$14.50

0.13 (0.90%)

, BAC

Bank of America

$31.69

-0.18 (-0.56%)

08:55
02/23/18
02/23
08:55
02/23/18
08:55
Options
Notable open interest changes for February 23rd »

Thursday's total…

GE

General Electric

$14.50

0.13 (0.90%)

BAC

Bank of America

$31.69

-0.18 (-0.56%)

AMD

AMD

$11.84

0.12 (1.02%)

ILG

ILG

$32.28

-0.03 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 13

    Mar

  • 14

    Mar

  • 15

    Mar

SLCA

U.S. Silica

08:55
02/23/18
02/23
08:55
02/23/18
08:55
Recommendations
U.S. Silica analyst commentary  »

U.S. Silica selloff after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

08:55
02/23/18
02/23
08:55
02/23/18
08:55
Conference/Events
The Washington Journal to hold a discussion on tax reform »

Tim Huelskamp, President…

VOYA

Voya Financial

$50.71

0.19 (0.38%)

08:54
02/23/18
02/23
08:54
02/23/18
08:54
Conference/Events
Voya Financial management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.